Related Experiment Video
Updated: May 6, 2026

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
Published on: April 9, 2013
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells
B Michael Silber1, Joel R Gever, Zhe Li
1Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143, United States; Department of Neurology, University of California, San Francisco, CA 94143, United States; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, United States.
Abstract:
During prion diseases, a normally benign, host protein, denoted PrP(C), undergoes alternative folding into the aberrant isoform, PrP(Sc). We used ELISA to identify and confirm hits in order to develop leads that reduce PrP(Sc) in prion-infected dividing and stationary-phase mouse neuroblastoma (ScN2a-cl3) cells. We tested 52,830 diverse small molecules in dividing cells and 49,430 in stationary-phase cells. This led to 3100 HTS and 970 single point confirmed (SPC) hits in dividing cells, 331 HTS and 55 confirmed SPC hits in stationary-phase cells as well as 36 confirmed SPC hits active in both. Fourteen chemical leads were identified from confirmed SPC hits in dividing cells and three in stationary-phase cells. From more than 682 compounds tested in concentration-effect relationships in dividing cells to determine potency (EC50), 102 had EC50 values between 1 and 10 μM and 50 had EC50 values of <1 μM; none affected cell viability. We observed an excellent correlation between EC50 values determined by ELISA and Western immunoblotting for 28 representative compounds in dividing cells (R(2)=0.75; p <0.0001). Of the 55 confirmed SPC hits in stationary-phase cells, 23 were piperazine, indole, or urea leads. The EC50 values of one indole in stationary-phase and dividing ScN2a-cl3 cells were 7.5 and 1.6 μM, respectively. Unexpectedly, the number of hits in stationary-phase cells was ~10% of that in dividing cells. The explanation for this difference remains to be determined.
Insights
Researchers screened over 100,000 compounds to find drugs that reduce abnormal prion protein (PrPSc) in cells. They identified promising chemical leads, including an indole compound, with potential for treating prion diseases.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Prion diseases involve the misfolding of cellular prion protein (PrPC) into an aberrant isoform (PrPSc).
- Developing therapeutic strategies to reduce PrPSc levels is crucial for treating prion diseases.
Purpose of the Study:
- To identify and confirm small molecule drug leads that reduce PrPSc levels in prion-infected mouse neuroblastoma cells.
- To evaluate the potency and efficacy of identified compounds in both dividing and stationary-phase cells.
Main Methods:
- High-throughput screening (HTS) of over 52,000 diverse small molecules in dividing ScN2a-cl3 cells and over 49,000 in stationary-phase cells.
- Enzyme-linked immunosorbent assay (ELISA) was used for hit identification and confirmation.
- Concentration-effect relationships were determined to establish EC50 values and assess cell viability.
Main Results:
- 3100 HTS and 970 single point confirmed (SPC) hits were identified in dividing cells; 331 HTS and 55 SPC hits in stationary-phase cells.
- Fourteen chemical leads were identified from dividing cells and three from stationary-phase cells.
- Potent compounds with EC50 values <1 μM were identified, with one indole lead showing efficacy in both cell states.
Conclusions:
- This study successfully identified numerous chemical leads with the potential to reduce PrPSc levels.
- The findings provide a foundation for developing novel therapeutics against prion diseases.
- A significant difference in hit rates between dividing and stationary-phase cells was observed, warranting further investigation.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Negative Regulator Molecules
Inhibitors of Viral Protein Synthesis

